PX-316 是一种 Akt 抑制剂,可使 Akt 磷酸化,但不抑制 PDK1 或 PKC 的磷酸化,并能特异性增加一组线粒体相关基因的表达,可用于结肠癌和乳腺癌的研究。
产品编号: MS-I56922 CAS No.: 253440-95-8 分子式: C28H57O10P 分子量: 584.72
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PX-316 是一种 Akt 抑制剂,可使 Akt 磷酸化,但不抑制 PDK1 或 PKC 的磷酸化,并能特异性增加一组线粒体相关基因的表达,可用于结肠癌和乳腺癌的研究。

生物实验数据

生物活性 PX-316 is an Akt inhibitor that induces Akt phosphorylation without inhibiting PDK1 or PKC phosphorylation, specifically increases the expression of a set of mitochondria-related genes, and can be used in research on colon cancer and breast cancer.
IC50 & Target

Akt

 

体外研究
(In Vitro)

PX-316 (0-15 μM,2 小时) 特异性抑制 HT-29 人结肠癌细胞中 Akt 的激活 (IC50 = 1.7 μM),而不影响上游激酶 PDK1 或相关激酶 PKC。
PX-316 (0.5-20 μM,3 天) 抑制 MCF-7 和 HT-29 细胞的增殖。

Western Blot Analysis

Cell Line: HT-29 human colon cancer cells
Concentration: 0 μM, 5 μM, 10 μM, 15 μM
Incubation Time: 2 h
Result: Inhibited EGF-induced Akt phosphorylation (phosphorylation of Ser473 site) in a concentration-dependent manner with an IC50 value of 1.7 μM, but did not inhibit PDK1 phosphorylation (Ser241 site) or PKC phosphorylation (Thr638/641 site).
体内研究
(In Vivo)

PX-316 (37.5-150 mg/kg,腹腔注射,单次) 能有效抑制 HT-29 细胞异种移植小鼠模型中的 Akt 信号通路及其下游靶点,且多次给药后仍能维持抑制作用。
PX-316 (50-150 mg/kg,腹腔注射,单次,连续4-10天) 在两种不同的人类肿瘤小鼠异种移植模型 (MCF-7 和 HT-29) 中均表现出剂量和给药方案依赖性的抗肿瘤活性。

Animal Model: HT-29 colon cancer cells(107)were injected subcutaneously into the flanks of male severe combined immunodeficient (scid) mice.
Dosage: 37.5 mg/kg, 75 mg/kg, 150 mg/kg
Administration: I.p., once
Result: A single administration of 150 mg/kg inhibited Akt (Ser473) phosphorylation in tumors by up to 78% at 10 hours, recovering to 34% inhibition after 48 hours.
The half-maximal inhibitory dose (ID50) for Akt phosphorylation in tumors was 80 mg/kg, while the ID50 for normal tissue (spleen) was 128 mg/kg.
At a concentration of 150 mg/kg, phosphorylation of GSK-3β (Ser9), a downstream target of Akt, was also inhibited, with inhibition rates of 53% and 77% at 5 hours and 24 hours, respectively.
At a dose of 75 mg/kg, whether administered once daily for 5 consecutive days or once every 3 days for 5 consecutive days, Akt activity was consistently inhibited (inhibition rate of 70%-80%).
Animal Model: MCF-7 human breast cancer cells (107 cells) were mixed with Matrigel and subcutaneously injected into the flank of female SCID mice. One day before tumor cell inoculation, mice were subcutaneously implanted with 60-day sustained-release 17-β-estradiol pellets to support the growth of this estrogen-dependent tumor.
Dosage: 50 mg/kg, 75 mg/kg, 100 mg/kg
Administration: I.p., once daily for 10 days, 10 days and 5 days, respectively
Result: 75 mg/kg showed a good inhibitory effect (T/C = 20%), while 100 mg/kg showed a slightly weaker effect (T/C = 39%).
Animal Model: HT-29 human colon cancer cells (107 cells) were subcutaneously injected into the flank of SCID mice.
Dosage: 100 mg/kg, 150 mg/kg
Administration: I.p., once daily for 4 days
Result: Caused growth inhibition of 5-day HT-29 colon cancer xenografts when administered for 4 days IP at 150 mg/kg/day (T/C33.3%, P<0.05) but no activity at 100 mg/kg/day.

化学信息

分子量 584.72
分子式 C28H57O10P
CAS No. 253440-95-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础